John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.